RxDoctor Payments Data

Ahmed Bhatti, MD

Pulmonary Disease · Granbury, TXNPI 1023190055

Payments from drug & device makers

$51,062in general payments, 2019–2025

Across 989 payments — averaging $51.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$23K
  • AstraZeneca$9K
  • Intuitive Surgical$5K
  • GSK$3K
  • Harmony Biosciences LLC$2K
  • Boehringer Ingelheim$1K
  • plus $9K from 39 others

What the payments were for

  • Consulting fees$15,03629%
  • Speaking & faculty fees$12,47424%
  • Travel & lodging$1,3953%
  • Food & beverage$17,55234%
  • Education$4,6059%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,062 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$291,732
Medicare patients
1,043
Services billed
3,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter2,065$1,614,206
OfevNintedanib Esylate32$428,489
Spiriva RespimatTiotropium Bromide446$267,250
OpsumitMacitentan22$259,192
XywavSodium,calcium,mag,pot Oxybate14$232,408
ZemairaAlpha-1-Proteinase Inhibitor13$156,742
Breztri AerosphereBudesonide/Glycopyr/Formoterol186$136,826
Breo ElliptaFluticasone/Vilanterol231$108,348
Orenitram ErTreprostinil Diolamine11$79,153
Combivent RespimatIpratropium/Albuterol Sulfate120$69,211
Stiolto RespimatTiotropium Br/Olodaterol Hcl120$68,027
Pirfenidone33$62,657
Tadalafil16$51,853
Fluticasone-SalmeterolFluticasone Propion/Salmeterol240$30,850
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$30,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$2,635$1,781,6192,413 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$1,023$832,977718 claims
Actelion Pharmaceuticals US, Inc.Opsumit$524$259,19222 claims
AstraZenecaBreztri Aerosphere, Symbicort$8,563$167,007293 claims
CSL BehringZemaira$19$156,74213 claims
Axsome Therapeutics, Inc.Sunosi$331$24,55424 claims
PfizerEliquis$68$20,68318 claims
MerckDulera$66$4,41613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Granbury

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →